Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors.